GENE ONLINE|News &
Opinion
Blog

2021-12-03|

Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab

by Joy Lin
Share To

Barely a few days after licensing a pulmonary fibrosis drug to Italian pharma Chiesi, UCB has struck a second deal with Swiss pharma giant Novartis. The collaboration this time approaches $1.65 billion in value and involves two drugs, a small molecule inhibitor and a monoclonal antibody, designed to treat Parkinson’s Disease (PD). 

“This partnership has the potential to be transformational for people living with Parkinson’s disease,” said Dhaval Patel, Executive Vice President and Chief Scientific Officer at UCB, “as it will combine UCB’s expertise as a leader in the field of neurodegenerative disease with Novartis’ global capabilities and deep experience developing transformative, disease modifying treatments for a range of neurological conditions.”

Terms of the $1.65 Billion Collab 

 

The deal centers around two of UCB’s investigational drug candidates, UCB0599 and UCB7853. UCB0599 is an orally administered small molecule inhibitor that targets alpha-synuclein, a hallmark of PD, while UCB7853 is an anti-alpha-synuclein monoclonal antibody.

Under the deal, UCB and Novartis will jointly develop and fund global development of UCB0599, which is in Phase 2 trials. Novartis also gets an option to co-develop UCB7853 once its UCB-run Phase 1 study completes. 

Novartis will pay UCB $150 million upfront and close to $1.5 billion in milestones if regulatory and sales goals are met. UCB will lead commercial activities in Europe and Japan, while Novartis will be responsible for sales in the US and other countries. 

Alpha-Synuclein, an Evasive Target for PD

 

The misfolding of alpha-synuclein and toxic accumulation results in the death of neuronal cells, which contributes to PD. Reducing levels of this protein is thought to slow progression of PD. However, treatments targeting alpha-synuclein have given mixed results to date. 

Prior to partnering with UCB, Novartis had attempted to treat PD with Tasigna (nilotinib). Originally approved to treat leukemia, Tasigna was shown in a Georgetown University-sponsored Phase 2 study to reduce levels of alpha-synuclein and improved symptoms in patients with PD. 

Despite the promising results, a followup Phase 2 in 2019 by Northwestern University only confirmed Tasigna was safe to use but not clinically beneficial. The jury is still out on Tasigna, as extension data from the Georgetown study at 27 months appeared to show that higher doses (300mg) of Tasigna could still slow PD symptoms. 

Meanwhile, Roche and Prothena are attempting to crack PD with prasinezumab, another antibody that targets alpha-synuclein, despite revealing mixed Phase 2 results last year where the trial missed its primary endpoint. 

Another pair contending for PD treatments is AstraZeneca and Takeda. The two companies started way back in 2017 to co-develop an anti-alpha-synuclein antibody, MEDI1341. 

Other biotechs targeting alpha-synuclein include AC Immune and Inhibikase Therapeutics, while Biogen discontinued its candidate, cinpanemab, earlier this year after flopping in Phase 2. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
BIO Asia-Taiwan 2022: The Future Of CGT In Taiwan
2022-08-08
R&D
Monoclonal Antibody Discovered to Potentially Act Against All Coronaviruses
2022-07-25
LATEST
Orna Therapeutics Secures Multi-Billion RNA Deal With Merck After $221 Million Series B
2022-08-17
FDA Allows Sales of Over-the-Counter Hearing Aids After Five Years of Consideration
2022-08-17
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK’s Second Billion Dollar Acquisition Outprices their First of 2022
2022-08-16
Despite Global Acceptance, The UK Refuses to Buy AstraZeneca’s Evusheld, Citing ‘Insufficient Data’
2022-08-16
Antibody Treatment for Multiple Varieties of CoronaVirus
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-14
Bio Asia Pacific 2022
Tailand
2022-09-14
The Future of Health
Online
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!